NCT00156611UnknownPhase 2
ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease - A Randomized Prospective Trial (RIO-Trial)
University Hospital Tuebingen2 sites in 1 country420 target enrollmentStarted: January 2002Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Enrollment
- 420
- Locations
- 2
- Primary Endpoint
- Prevention of subacute occlusions within 30 days
Study Overview
Brief Summary
The Rio Study is a randomized, double blinded German- Swiss- Austria multi-centre trial on the efficacy and safety of ReoPro together with interventional recanalization of TASC D lesions in the SFA and popliteal artery.
Detailed Description
Purpose: The RIO trial is designed to test the efficacy of GP IIb/IIIa blockade on subacute reocclusions in patients with interventional recanalization of chronic occlusions in the superficial femoral and popliteal artery.
Methods: A total of 420 patients will be randomly assigned to ReoPro or placebo. Patients will be eligible for randomisation with occlusions longer than 5 cm. Doppler ultrasound follow-up will be at 30 days, and after 6, and 12 months.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with a history of peripheral artery disease with superficial femoral or popliteal artery occlusion, which mandates PTA or stent administration as first treatment modality. The history of peripheral artery occlusion has to be at least 6 weeks, and the target vessel occlusion has to be more than 5 centimeters in length.
- •Age between 18 and 90 years
Exclusion Criteria
- •Acute limb ischemia
- •Subacute ischemia with requires thrombolysis as first treatment modality
- •Active bleeding or known bleeding diathesis
- •Known severe hepatic or renal disorder (liver cirrhosis, stage B, C or serum creatinine > 2.5 mg%)
- •Hyperthyreosis
- •Diabetes mellitus treated with metformin
- •Known heparin induced thrombocytopenia (HIT, type 2)
- •Female sex with childbearing potential
- •Major surgery or trauma in past 6 weeks
- •History of stroke within the previous 2 years, or any stroke with a residual neurological deficit, or other CNS abnormality (e.g., intracranial neoplasm, arteriovenous malformation, or aneurysm)
- •Gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks
- •Administration of oral anticoagulants within the previous 7 days unless prothrombin time is < 1.2 times control (or international normalized ratio [INR] <1.4), or ongoing treatment with oral anticoagulants
- •History of bleeding diathesis of platelet count < 100,000/mm3
- •Arteriovenous malformations or aneurysms
- •Severe uncontrolled hypertension (treated sys. BP > 200 mm Hg, diast. BP > 100 mm Hg)
- •Hypertensive or diabetic retinopathy
- •Vasculitis
- •Known autoimmune disorders
- •Patient with aspirin intolerance
- •Contraindication or known allergic reactions to abciximab or murine proteins
- •Co-existent condition associated with a limited life expectancy (e.g., advanced cancer, end-stage congestive heart failure)
- •Participation in another clinical research study involving the evaluation of another investigational drug or device within 7 days prior to enrollment
- •Patient who has previously received a GP IIb/IIIa antagonist
Outcomes
Primary Outcomes
Prevention of subacute occlusions within 30 days
Secondary Outcomes
- Prevention of restenosis up to 3 years
- Prevention of target lesion revascularization
- Improvement of the clinical status
- Change of ABI
- Hospital days
- all secondary outcomes at 30 days, 6 months, one year, and 3 years (telephone contact after 3 years)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Unknown
Phase 2
Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the KneePatients Above 18 YearsNCT00163254University Hospital Tuebingen
Completed
Phase 2
The ROVO Study: Radial Optic Neurotomy for CVOCentral Retinal Vein OcclusionNCT00532142Rudolf Foundation Clinic
Completed
Phase 4
Ipratropium Bromide in Peri-Operative COPDPulmonary Disease, Chronic ObstructiveNCT01943552Boehringer Ingelheim192
Completed
Phase 2
Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture ReconstructionAcquired Bleeding DisorderTraumaNCT01601457Novo Nordisk A/S48
Completed
Phase 2
Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With ClopidogrelPeripheral Vascular DiseasesNCT00163267University Hospital Tuebingen80